Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy

MAYAKO UCHIDA, SAEKO MURATA, HANAE MORIKAWA, HIROKO YONEMITSU, SHIGERU ISHIDA, KIMITAKA SUETSUGU, TOSHIKAZU TSUJI, HIROYUKI WATANABE, TAKEHIRO KAWASHIRI, KOJI KATO, KEIKO HOSOHATA, TOSHIHIRO MIYAMOTO, NOBUAKI EGASHIRA, TSUTOMU NAKAMURA, KOICHI AKASHI and ICHIRO IEIRI
Anticancer Research April 2022, 42 (4) 2053-2060; DOI: https://doi.org/10.21873/anticanres.15686
MAYAKO UCHIDA
1Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, Japan;
2Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kyoto, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m-uchida@dwc.doshisha.ac.jp
SAEKO MURATA
2Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kyoto, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANAE MORIKAWA
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKO YONEMITSU
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGERU ISHIDA
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIMITAKA SUETSUGU
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIKAZU TSUJI
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI WATANABE
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
4Department of Pharmacy, Fukuoka Tokushukai Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKEHIRO KAWASHIRI
5Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI KATO
6Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIKO HOSOHATA
1Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHIRO MIYAMOTO
6Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUAKI EGASHIRA
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUTOMU NAKAMURA
1Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI AKASHI
6Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ICHIRO IEIRI
3Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Corrigenda - June 01, 2022

Abstract

Background/Aim: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin’s lymphoma patients. Patients and Methods: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data. Results: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%. Conclusion: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.

Key Words:
  • Chemotherapy
  • medication guidance sheet
  • adverse events
  • non-Hodgkin’s lymphoma
  • ESHAP±R therapy
  • Received January 16, 2022.
  • Revision received March 9, 2022.
  • Accepted March 10, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (4)
Anticancer Research
Vol. 42, Issue 4
April 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy
MAYAKO UCHIDA, SAEKO MURATA, HANAE MORIKAWA, HIROKO YONEMITSU, SHIGERU ISHIDA, KIMITAKA SUETSUGU, TOSHIKAZU TSUJI, HIROYUKI WATANABE, TAKEHIRO KAWASHIRI, KOJI KATO, KEIKO HOSOHATA, TOSHIHIRO MIYAMOTO, NOBUAKI EGASHIRA, TSUTOMU NAKAMURA, KOICHI AKASHI, ICHIRO IEIRI
Anticancer Research Apr 2022, 42 (4) 2053-2060; DOI: 10.21873/anticanres.15686

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy
MAYAKO UCHIDA, SAEKO MURATA, HANAE MORIKAWA, HIROKO YONEMITSU, SHIGERU ISHIDA, KIMITAKA SUETSUGU, TOSHIKAZU TSUJI, HIROYUKI WATANABE, TAKEHIRO KAWASHIRI, KOJI KATO, KEIKO HOSOHATA, TOSHIHIRO MIYAMOTO, NOBUAKI EGASHIRA, TSUTOMU NAKAMURA, KOICHI AKASHI, ICHIRO IEIRI
Anticancer Research Apr 2022, 42 (4) 2053-2060; DOI: 10.21873/anticanres.15686
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Corrigenda
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • chemotherapy
  • medication guidance sheet
  • Adverse events
  • non-Hodgkin’s lymphoma
  • ESHAP±R therapy
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire